Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.

Bush TL, Payton M, Heller S, Chung G, Hanestad K, Rottman JB, Loberg R, Friberg G, Kendall RL, Saffran D, Radinsky R.

Mol Cancer Ther. 2013 Nov;12(11):2356-66. doi: 10.1158/1535-7163.MCT-12-1178. Epub 2013 Aug 29.

2.

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.

Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, Ross S, Cee VJ, Deak HL, Hodous BL, Nguyen HN, Olivieri PR, Romero K, Schenkel LB, Bak A, Stanton M, Dussault I, Patel VF, Geuns-Meyer S, Radinsky R, Kendall RL.

Cancer Res. 2010 Dec 1;70(23):9846-54. doi: 10.1158/0008-5472.CAN-10-3001. Epub 2010 Oct 8.

3.

Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.

Cee VJ, Schenkel LB, Hodous BL, Deak HL, Nguyen HN, Olivieri PR, Romero K, Bak A, Be X, Bellon S, Bush TL, Cheng AC, Chung G, Coats S, Eden PM, Hanestad K, Gallant PL, Gu Y, Huang X, Kendall RL, Lin MH, Morrison MJ, Patel VF, Radinsky R, Rose PE, Ross S, Sun JR, Tang J, Zhao H, Payton M, Geuns-Meyer SD.

J Med Chem. 2010 Sep 9;53(17):6368-77. doi: 10.1021/jm100394y.

PMID:
20684549
4.

Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor.

Burgess TL, Sun J, Meyer S, Tsuruda TS, Sun J, Elliott G, Chen Q, Haniu M, Barron WF, Juan T, Zhang K, Coxon A, Kendall RL.

Mol Cancer Ther. 2010 Feb;9(2):400-9. doi: 10.1158/1535-7163.MCT-09-0824. Epub 2010 Feb 2.

5.

The impact of peak-kilovoltage settings on heterogeneity-corrected photon-beam treatment plans.

Kendall RL, Gifford KA, Kirsner SM.

Radiother Oncol. 2006 Nov;81(2):206-8. Epub 2006 Oct 27.

PMID:
17069913
6.

Kinetic mechanism of AKT/PKB enzyme family.

Zhang X, Zhang S, Yamane H, Wahl R, Ali A, Lofgren JA, Kendall RL.

J Biol Chem. 2006 May 19;281(20):13949-56. Epub 2006 Mar 15.

7.

The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase.

Bilodeau MT, Rodman LD, McGaughey GB, Coll KE, Koester TJ, Hoffman WF, Hungate RW, Kendall RL, McFall RC, Rickert KW, Rutledge RZ, Thomas KA.

Bioorg Med Chem Lett. 2004 Jun 7;14(11):2941-5.

PMID:
15125964
8.

Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors.

Fraley ME, Arrington KL, Hambaugh SR, Hoffman WF, Cunningham AM, Young MB, Hungate RW, Tebben AJ, Rutledge RZ, Kendall RL, Huckle WR, McFall RC, Coll KE, Thomas KA.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):2973-6.

PMID:
12941314
9.

Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR.

Bilodeau MT, Cunningham AM, Koester TJ, Ciecko PA, Coll KE, Huckle WR, Hungate RW, Kendall RL, McFall RC, Mao X, Rutledge RZ, Thomas KA.

Bioorg Med Chem Lett. 2003 Aug 4;13(15):2485-8.

PMID:
12852948
10.

Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics.

Fraley ME, Rubino RS, Hoffman WF, Hambaugh SR, Arrington KL, Hungate RW, Bilodeau MT, Tebben AJ, Rutledge RZ, Kendall RL, McFall RC, Huckle WR, Coll KE, Thomas KA.

Bioorg Med Chem Lett. 2002 Dec 16;12(24):3537-41.

PMID:
12443771
11.

Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors.

Fraley ME, Hoffman WF, Rubino RS, Hungate RW, Tebben AJ, Rutledge RZ, McFall RC, Huckle WR, Kendall RL, Coll KE, Thomas KA.

Bioorg Med Chem Lett. 2002 Oct 7;12(19):2767-70.

PMID:
12217372
12.

Discovery of a small molecule insulin mimetic with antidiabetic activity in mice.

Zhang B, Salituro G, Szalkowski D, Li Z, Zhang Y, Royo I, Vilella D, Díez MT, Pelaez F, Ruby C, Kendall RL, Mao X, Griffin P, Calaycay J, Zierath JR, Heck JV, Smith RG, Moller DE.

Science. 1999 May 7;284(5416):974-7.

13.

Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues.

Kendall RL, Rutledge RZ, Mao X, Tebben AJ, Hungate RW, Thomas KA.

J Biol Chem. 1999 Mar 5;274(10):6453-60.

14.

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate.

Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT.

Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8795-800.

15.
16.

Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes.

Arfin SM, Kendall RL, Hall L, Weaver LH, Stewart AE, Matthews BW, Bradshaw RA.

Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7714-8.

17.

Specificity of vascular endothelial cell growth factor receptor ligand binding domains.

Kendall RL, Wang G, DiSalvo J, Thomas KA.

Biochem Biophys Res Commun. 1994 May 30;201(1):326-30.

PMID:
8198591
18.
20.

Erythrocyte alloantigen loci Ea-D and Ea-I map to chromosome 1 in the chicken.

Bitgood JJ, Kendall RL, Briles RW, Briles WE.

Anim Genet. 1991;22(6):449-54.

PMID:
1789498
21.

Cotranslational amino-terminal processing.

Kendall RL, Yamada R, Bradshaw RA.

Methods Enzymol. 1990;185:398-407. No abstract available.

PMID:
2143260
22.

Expression of synthetic thaumatin genes in yeast.

Lee JH, Weickmann JL, Koduri RK, Ghosh-Dastidar P, Saito K, Blair LC, Date T, Lai JS, Hollenberg SM, Kendall RL.

Biochemistry. 1988 Jul 12;27(14):5101-7.

PMID:
3167035
23.

Preventive dentistry: fact and fiction.

Kendall RL.

Bull N Y State Soc Dent Child. 1970 Nov;22(1):6-7. No abstract available.

PMID:
5277572

Supplemental Content

Loading ...
Support Center